Exome and transcriptome sequences uncovered features that characterized testicular germ cell tumors by whether they did or did not respond to treatment.
The Children's National team will return diagnostic results to patients and Regeneron will use the genomic data in its drug development pipeline.
Response to a low toxicity drug called decitabine was most pronounced in acute myeloid leukemia and myelodysplastic syndrome cases with TP53 mutations.
By sequencing ancient and contemporary indigenous individuals from Canada's Pacific Coast, researchers uncovered clues to a post-colonization population bottleneck.
Mount Sinai is the latest healthcare provider to link up with Regeneron's Genetics Center, to pair NGS data with electronic medical record data.
Using exome sequence and phenotyping data for individuals from longitudinal population studies, investigators began parsing pathogenic mutation effects in the genes.
The exome-sequencing consumer genomics startup has added George Church and Dietrich Stephan to its advisory board, along with several others.
A team led by Stanford's Mike Snyder is collaborating with investigators from the International Genetics & Translational Research in Transplantation Network (iGeneTrain) consortium.
Two independent research teams linked plasmepsin 2 and plasmepsin 3 gene amplifications to piperaquine resistance.
By analyzing mutations in tumors from a broad swath of tobacco smoke-related cancer types, investigators identified more than two-dozen mutational signatures.
Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.
Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.
The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.
In Science this week: genetically modified flu virus could be key to new live vaccines, and more.